Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Circ J ; 77(6): 1436-44, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23470885

RESUMO

BACKGROUND: CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is related to low responsiveness to clopidogrel, which is a risk factor for ischemic cardiac events. The contribution of these genotypes to platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stenting was evaluated. METHODS AND RESULTS: A total of 155 Japanese patients were classified according to their CYP2C19 loss-of-function genotype. Platelet reactivity was assayed by plasma levels of soluble P-selectin and platelet-derived microparticles, light transmittance aggregometry induced by ADP (ADP-LTA), shear stress-induced platelet aggregometry, vasodilator-stimulated phosphoprotein phosphorylation (VASP) index and the VerifyNow-P2Y12 assay. Linear and logistic regression models were used to assess the associations between CYP2C19 loss-of-function genotype and high on-treatment platelet reactivity. In total, 62 patients (40.0%) were extensive metabolizers (EMs), 70 (45.2%) were intermediate metabolizers (IMs) and 23 (14.8%) were poor metabolizers (PMs). ADP-specific assays (ADP-LTA, the VASP index and VerifyNow-P2Y12) differed according to CYP2C19 genotype, with a significant gene-dose effect (PMs>IMs>EMs). CYP2C19 loss-of-function carrier status was associated with more frequent high platelet reactivity. CYP2C19 loss-of-function genotype alone could explain 12.2%, 14.3%, and 14.7% of the variability in the ADP-LTA, VASP and VerifyNow-P2Y12 assays, respectively. CONCLUSIONS: CYP2C19 loss-of-function genotype is associated with more frequent high platelet reactivity, as assessed by ADP-specific platelet function tests, in Japanese patients.


Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Vasos Coronários , Isquemia Miocárdica/genética , Isquemia Miocárdica/terapia , Agregação Plaquetária/genética , Polimorfismo Genético , Stents , Ticlopidina/análogos & derivados , Hidrocarboneto de Aril Hidroxilases/metabolismo , Povo Asiático , Moléculas de Adesão Celular/sangue , Clopidogrel , Citocromo P-450 CYP2C19 , Humanos , Japão , Proteínas dos Microfilamentos/sangue , Isquemia Miocárdica/sangue , Isquemia Miocárdica/patologia , Isquemia Miocárdica/fisiopatologia , Selectina-P/sangue , Fosfoproteínas/sangue , Inibidores da Agregação Plaquetária , Testes de Função Plaquetária , Estudos Prospectivos , Ticlopidina/administração & dosagem
2.
Nihon Kokyuki Gakkai Zasshi ; 49(7): 496-500, 2011 Jul.
Artigo em Japonês | MEDLINE | ID: mdl-21842685

RESUMO

A 64-year-old diabetic man was admitted because his general condition had not improved despite the admini stration of voriconazole in another hospital, and his condition had become critical. Chest CT demonstrated a large fungus ball and consolidation around a cavity in the right lung. Aspergillusfumigatus was detected on a sputum culture. Based on these findings, we diagnosed invasive aspergillosis and administered high-dose (5mg/kg) liposomal amphotericin B (L-AMB) for 8 weeks, which resulted in the improvement of his general condition and the disappearance of the fungus ball, without severe adverse events.


Assuntos
Anfotericina B/administração & dosagem , Antifúngicos/administração & dosagem , Aspergilose Pulmonar/tratamento farmacológico , Humanos , Lipossomos , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA